A Phase 1 Study of Copanlisib(Phosphatidylinositol-3 Kinase Inhibitor) in Combination With Gemcitabine (Treatment A) or Cisplatin Plus Gemcitabine (Treatment B) in Subjects With Advanced Solid Malignancy
Phase of Trial: Phase I
Latest Information Update: 18 Jan 2018
At a glance
- Drugs Copanlisib (Primary) ; Cisplatin; Gemcitabine
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Bayer
- 18 Jan 2018 Results assessing safety, pharmacokinetics and clinical response, published in the British Journal of Cancer.
- 11 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 29 Oct 2015 Planned End Date changed from 1 Nov 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History